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Alzheimer’s disease (AD) is emerging as the most prevalent and socially disruptive illness
of aging populations, as more people live long enough to become affected. Although AD
is placing a considerable and increasing burden on society, it represents the largest unmet
medical need in neurology, because current drugs improve symptoms, but do not have
profound disease-modifying effects. AlthoughAD pathogenesis is multifaceted and difﬁcult
to pinpoint, genetic and cell biological studies led to the amyloid hypothesis, which posits
that amyloid β (Aβ) plays a pivotal role in AD pathogenesis. Amyloid precursor protein
(APP), as well as β- and γ-secretases are the principal players involved in Aβ production,
while α-secretase cleavage on APP prevents Aβ deposition. The association of early onset
familial AD with mutations in the APP and γ-secretase components provided a potential
tool of generating animal models of the disease. However, a model that recapitulates all
the aspects of AD has not yet been produced. Here, we face the problem of modeling
AD pathology describing several models, which have played a major role in deﬁning critical
disease-related mechanisms and in exploring novel potential therapeutic approaches. In
particular, we will provide an extensive overview on the distinct features and pros and
contras of different AD models, ranging from invertebrate to rodent models and ﬁnally
dealing with computational models and induced pluripotent stem cells.
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INTRODUCTION
Alzheimer’s disease (AD), the major cause of dementia, is associ-
ated with progressive memory loss and severe cognitive decline.
Initially mild cognitive impairment and deﬁcits in short-term
and spatial memory appear, but the symptoms become more
severe with disease progression, eventually culminating in loss of
executive function.
The immense social and economic ramiﬁcations of AD have
generated major efforts toward obtaining a better understand-
ing of the disease and toward developing therapeutic agents for
its treatment. Regrettably, however, there is no remission in the
progression of AD, nor are there any disease-stabilizing drugs
currently available.
The neuropathology is characterized by the presence of intra-
cellular and extracellular protein or peptide aggregates: the
hyperphosphorylated tau, assembled into the paired helical ﬁl-
aments within neuroﬁbrillary tangles (NFTs) and swollen neuritis
(Grundke-Iqbal et al., 1986), and the Amyloid β (Aβ) peptides
existing in extracellular β-pleated sheet conformations assembled
into oligomers, in amyloid plaques (Glenner andWong, 1984).
Although AD pathogenesis is multifaceted and difﬁcult to pin-
point, genetic and pathological evidence strongly supports the
amyloid cascade hypothesis of AD, which posits that Aβ has an
early and vital role in AD, since it triggers a cascade of events
leading to synaptic dysfunction, tau pathology, and neuronal loss
(Hardy and Selkoe, 2002).
The production of Aβ is mediated by the concerted action
of two different secretases, namely β-secretase [β-site amyloid
precursor protein (APP)-cleaving enzyme, BACE] and γ-secretase,
showing a proteolytic action on the APP (Haass, 2004). BACE
cleaves at the N-terminus of the Aβ sequence, releasing into
the extracellular space a soluble fragment, designated sAPPβ,
and leaving attached to the cellular membrane a 99 aminoacids
(aa) long C-terminal fragment (CTF99), which is then cleaved
by γ-secretase at the C-terminus of the Aβ domain (Figure 1).
Proteolysis by γ-secretase is heterogeneous: most of the full-
length Aβ species produced is a 40-residues peptide (Aβ40),
whereas a small proportion is a 42-residues COOH-terminal
variant (Aβ42; Esler and Wolfe, 2001). γ-secretase is a multi-
meric complex thought to be made up of an essential quartet
of transmembrane proteins – presenilin 1 (or 2), nicastrin, Aph-1
(anterior pharynx-defective 1), and Pen-2 (presenilin enhancer 2;
Edbauer et al., 2003).
On the other hand, α-secretase is the main protagonist of the
physiological APP metabolic pathway.
It has been demonstrated that the constitutively cleaving α-
secretase activity is selectivelymediated byADAM10 (a disintegrin
and metalloprotease) in neurons (Jorissen et al., 2010; Kuhn et al.,
2010). ADAM10 cleaves APP on the C-terminal side of residue
16 of the Aβ sequence, destroying this amyloidogenic component
and, thus, preventing the formation and deposition of plaques
(Figure 1).
Two different forms of AD have been described: (i) early
onset familial AD (FAD; Hornsten et al., 2007), associated with
mutations in the genes encoding APP, presenilin 1 (PSEN1) and
presenilin 2 (PSEN2), and accounting for less than 5% of total AD;
and (ii) a more common late onset AD (LOAD), in which a main
risk factor is expression of the ε4 allele of the apolipoprotein E
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FIGURE 1 | Scheme of amyloid cascade. APP is the precursor of the
amyloid β peptide (Aβ), here it is shown the proteolytic cleavage of APP by the
α-secretase (ADAM10), which precludes the formation of amyloidogenic
peptides and leads to the release of sAPPα, while β-secretase (BACE)
cleaves APP at the N-terminus of the Aβ sequence, releasing into the
extracellular space sAPPβ. Proteolysis of the APP C-terminal fragments by
γ-secretase is the last processing step resulting in the generation of p3 and
Aβ, respectively.
gene (APOE). Speciﬁcally, the presence of two ε4 alleles increases
by approximately 12-fold the risk for AD and lowers the age of
onset of the disease by about 15 years (Kim et al., 2009).
Alzheimer’s disease-causingmutations inAPP result in an over-
all increase of the production of Aβ. More than 60 mutations have
been identiﬁed in presenilin 1 and they affect APP processing so
that more Aβ 42 is produced (Selkoe, 2000). Mutations in prese-
nilin 2 are rare but are also thought to affect the processing of APP
toward amyloidosis. Mutations in the gene encoding tau (MAPT)
have not been linked to AD, although they are associated with
other dementias such as frontal temporal lobe dementia (Goedert
and Spillantini, 2000).
The links betweenAPP,presenilin 1, and FADprovided a poten-
tial tool of generating animal models of the disease to turn these
genetic information, in the form of pathogenic mutations, into
clinically useful drugs against the human disease.
Animal models of AD have been designed to reproduce vari-
ous components of the pathological, biochemical, and behavioral
characteristics of AD in order to understand the consequences of
the pathological and biochemical changes that occur as the disease
progresses, and investigate the effectiveness of potential pharma-
cotherapies (Wenk and Olton, 1987, 1989). An animal model is
useful only if it leads to the development of an effective therapy or
provides a better understanding of the biological mechanisms that
underlie the symptoms of the disease. Animal models of AD have
providedmuch information on the function of the basal forebrain
system and have been used to investigate the potential effective-
ness of various pharmacotherapies designed to reverse speciﬁc
symptoms.
However, a model that recapitulates all the aspects of AD has
not yet been produced, even if there are transgenic lines that offer
robust and relatively faithful reproductions of a subset of its fea-
tures. Nevertheless, one barrier to the efﬁciency of drug discovery
efforts in the area of AD therapeutics is the time and labor intensive
nature of animal studies using transgenic mice.
In light of these considerations, this review provides an exten-
sive overview on several AD models, ranging from invertebrate
to rodent animal models, and ﬁnally explores new perspec-
tives, such as induced pluripotent stem cells and computational
models.
NON-RODENT MODELS OF ALZHEIMER’S DISEASE
INVERTEBRATE MODELS
A majority of the genes linked to human disease, such as AD,
belong to evolutionarily conserved pathways found in simpler
organisms. The genes and pathways of these simple organisms
can be genetically and pharmacologically manipulated to better
understand the function of their orthologs in vivo, and to investi-
gate how these genes are involved in the pathogenesis of different
diseases. Often thesemanipulations can be performedmuchmore
rapidly in ﬂies andworms than inmammals, and can generate high
quality in vivo data that are translatable to mammalian systems.
Other qualities also make these organisms particularly well-suited
to the study of human disease. Invertebrate models are relatively
inexpensive, easy to work with, have short lifespans, and often
have very well-characterized and stereotypical development and
behavior. This is particularly true for the two invertebrate model
organisms: Caenorhabditis elegans and Drosophila melanogaster.
The modeling of age-related neurodegenerative diseases, such
as AD, in invertebrate systems generally relies on two different
methods: (1) genetic manipulation of the orthologs invertebrate
genes that are associated with disease-causing pathways, and/or
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(2) expression of human versions of disease-related proteins in
the model organism. Indeed, several pathways that play a vital role
in normal development were ﬁrst identiﬁed and investigated in
Drosophila (Nusslein-Volhard andWieschaus, 1980); also, genetic
regulation of programmed cell death and RNA interference were
ﬁrst elucidated in C. elegans (Brenner, 1974; Ellis and Horvitz,
1986; Fire et al., 1998). Additionally, some of the major molecular
pathways that regulate normal aging were found in both of these
model organisms as well (Lin et al., 1998; Zou et al., 2000; Zhan
et al., 2007; Smith et al., 2008), illustrating the power and produc-
tivity of studying age-related disease mechanisms in invertebrate
systems.
While vertebratemodelsmay provide a closermatch to humans
evolutionarily, invertebrate models can still provide useful infor-
mation about disease progression and the function of genes
involved in AD.
Analysis of invertebrate orthologs of AD genes
Most of the proteins associated with AD are evolutionarily con-
served in Drosophila and C. elegans, making these organisms
attractive model systems for understanding the conserved molec-
ular functions of these genes. For instance, the ortholog of the
human APP protein is Apl-1 in C. elegans (Daigle and Li, 1993)
and Appl in Drosophila (Rosen et al., 1989; Luo et al., 1990). In C.
elegans, Apl-1 is expressed in multiple tissues and is essential for
viability (Hornsten et al., 2007). In Drosophila, Appl transcripts
are mainly localized in the cortical region of the ﬂy nervous sys-
tem (Martin-Morris and White, 1990). Luo et al. (1992) showed
that there is a functional conservation between ﬂy Appl and
human APP proteins, as the behavioral defects observed by a null
mutant of ﬂy Appl are rescued by expressing the human APP pro-
tein in these mutants. The functional ortholog of α-secretase in
the ﬂy is the kuzbanian gene (Rooke et al., 1996; Allinson et al.,
2003). In C. elegans, there are two α-secretase orthologs, sup-
17 which is ortholog to mammalian ADAM10 (Tax et al., 1997;
Wen et al., 1997) and adm-4 which is ortholog to mammalian
ADAM17/TACE (Jarriault and Greenwald, 2005). To date, there
is no evidence of β-secretase activity in C. elegans (Ewald and
Li, 2010). Recently, however, a functional β-secretase ortholog was
identiﬁed inDrosophila (Carmine-Simmen et al., 2009). Carmine-
Simmen et al. (2009) found that the ﬂyAppl protein can be cleaved
by Drosophila BACE (dBACE) to generate a Drosophila Appl-
speciﬁc Aβ peptide. This ﬂy Aβ peptide also shows neurotoxic
properties similar to humanAβ peptides (Carmine-Simmen et al.,
2009), providing intriguing evidence to suggest conservation in
the role of Aβ peptide-induced toxicity across species. Similarly,
expression of either human or Drosophila α-cleaved ectodomains
was shown to have neuroprotective effects inmultiple ﬂy neurode-
generation mutants (Wentzell et al., 2012), suggesting conserved
functions of this domain across species as well. Each member
of the mammalian γ-secretase complex (presenilin 1, presenilin
2, nicastrin, Aph-1, Pen-2; Kimberly et al., 2003) is also con-
served in both ﬂies and worms (Levitan and Greenwald, 1995,
1998; Hong and Koo, 1997; Li and Greenwald, 1997; Goutte
et al., 2000; Wen et al., 2000; Chung and Struhl, 2001; Francis
et al., 2002). Both ﬂies and worms contain an ortholog of tau
as well.
In addition to the APP and the secretases genes, invertebrate
models are useful tools to understand the function of genes
that have been associated with increased risk for LOAD. Sev-
eral genetic association studies have identiﬁed common variants
of genes including CLU (clusterin), BIN1 (bridging integrator
1), and PICALM (phosphatidylinositol binding clathrin assem-
bly protein) as potential LOAD-related risk genes (Bertram et al.,
2007). Invertebrate orthologs of these genes have been associated
with cellular cytoskeletal dynamics, clathrin-mediated endocyto-
sis, and postsynaptic exocytosis (Nonet et al., 1999; Mathew et al.,
2003; Bao et al., 2005; Dickman et al., 2006). See Figure 2 for a
schematic representation.
Caenorhabditis elegans
Caenorhabditis elegans offers an efﬁcient in vivo system to exam-
ine the toxic outcomes of overexpression of proteins and peptides
that are prone to pathological misfolding (Teschendorf and Link,
2009). C. elegans can be further used as a cost-effective platform
for discovering compounds that protect against the toxicity asso-
ciated with these misfolded proteins. Simple animal models, like
C. elegans, do not need to recapitulate all pathological aspects of
the respective diseases. Indeed, the simplicity of this model may be
advantageous; the potentially confounding behavioral and cogni-
tive responses typical of the higher vertebrate are absent. Instead,
rapid and clear toxic phenotypes may be preferable for screening
strategies, facilitating identiﬁcation of structure–activity relation-
ships. The well-developed genetics and short life cycle of C. elegans
allow it to be used in ways that are time and cost-prohibitive in
vertebrate systems. As such C. elegans represents a complemen-
tary tool in drug discovery that may be employed before testing in
vertebrate models, to expedite development of new therapeutics.
To be useful for drug discovery this model must be predictive of
efﬁcacy in traditional vertebrate models.
Caenorhabditis elegans constitutes an excellent genetic system
for studying molecular pathways involved in AD and tauopathies.
Its capacity to express tau human proteins makes it a good ani-
mal model for these diseases. As mentioned above, the nematode
has the gene Apl-1, which encodes two almost identical isoforms
orthologs to the human APP, although it does not produce Aβ
peptides because it lacks the β-secretase cleavage (Wentzell and
Kretzschmar, 2010). Interestingly, earlier transgenic models of
expressing human-Aβ in C. elegans do not accumulate the full
length Aβ1−42 as expected, but predominantly a Aβ3−42 trunca-
tion product due to an aberrant cleavage of the N-terminal signal
peptide incorporated in the C. elegans transgene. In vitro analysis
demonstrates that Aβ3−42 self-aggregates like Aβ1−42, but more
rapidly, and forms ﬁbrillar structures. TheAβ3−42 peptide is also a
more potent initiator of Aβ1−40 aggregation (McColl et al., 2009).
To test the toxic effects of theAβ3−42 a paralysis assaywas done and
C. elegans expressing Aβ3−42 showed an age-dependent paralysis
phenotype. This ﬁnding makes C. elegans a good model to study
the toxic effects and processing of Aβ3−42. However, Aβ3−42 does
not signiﬁcantly contribute to the Aβ found in human AD brain.
A C. elegans model expressing a more disease relevant form of
Aβ is required in order to fully exploit this system for drug discov-
ery. Thismodel, expressingAβ1−42, was generated byMcColl et al.
(2012). To achieve correct signal peptide cleavage from theAβ1−42
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FIGURE 2 |Vertebrate and invertebrate orthologs genes. Most of the
proteins associated with AD are evolutionarily conserved in Drosophila and
Caenorhabditis elegans making these organisms attractive model systems to
better understand the conserved molecular functions of these genes linked to
human disease. On the other hand, zebraﬁsh (Danio rerio) is a promising mo-
del organism to study various central nervous system disorders, including AD.
they inserted two additional aa (-DA-) between the synthetic sig-
nal peptide and the Aβ peptide corrected the cleavage, resulting in
expression of full lengthAβ1−42. Thismodel also provides a useful
tool to explore the mechanism(s) of Aβ1−42 toxicity.
In light of the above, C. elegans is proving useful as an in
vivo molecular genetic model for understanding basic mechanis-
tic pathways of complex human neurological diseases as AD. The
nematode can be used both as a monogenic model studying par-
ticular genes that are orthologs of human genes and as a versatile
organism that allows transgenic expression of human genes. In
addition, C. elegans makes available a well-characterized system
in that neurodevelopment is known at the cellular level, mak-
ing it possible to observe developmental features simultaneously
with an analysis of molecular and behavioral phenotypes. Fur-
thermore, since the nematode is only a millimeter long and its
behavior can bemonitored in liquid, it may be used as a system for
whole-animal high-throughput screening, whichmight be helpful
for ﬁnding new and speciﬁc clinical therapeutic drugs.
Droshophila
During the last decade, Drosophila has emerged as a power-
ful model to study human neurodegenerative diseases including
AD. The short generation time (∼10 days) and short lifespan
(∼60–80 days) make it particularly amenable to study such
age-relateddisorders.Moreover, genome studies have revealed that
∼70%of knowndisease-causing genes in humans are conserved in
ﬂies including several genes implicated in AD such as APP (Appl),
PSEN (Psn), and tau (tau; Reiter et al., 2001). The development
of Drosophila has also been extensively characterized and many
tools are available to determine the effect of mutations on speciﬁc
cell/tissue types, including neurons. Techniques to generate trans-
genic ﬂies have also been established including several methods
to express genes in a spatially and temporally restricted manner.
Finally, synaptic activity can be measured using electrophysiologi-
cal and imaging techniques fromboth the neuromuscular junction
and more recently, the adult central nervous system (CNS). Genes
identiﬁed as being potentially involved in AD progression can also
be examined for their effects on various behaviors including
locomotion and learning and memory. Various tools available in
ﬂies can be used to developmodels that reproduce the key features
of AD including plaques, tangles, memory defects, and death.
As far as concern behavioral analysis, longevity measurement
provides a statistically robust test of the neurological integrity
of a ﬂy. Although the cause of death is not clear, it is probably
related to a combination of behavioral deﬁcits that impair feeding
and hazard avoidance (Crowther et al., 2006). In ﬂies the most
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widely used behavioral assays that are employed are Pavlovian
conditioning tests of memory and learning (Iijima et al., 2004,
2008) and locomotor assays (Iijima et al., 2004; Crowther et al.,
2005, 2006; Rival et al., 2009). Subtle changes in locomotor behav-
ior characterize the early stages of neuronal dysfunction, e.g.,
Drosophila models of AD show a signiﬁcant decrease in climbing
ability.
To date, the majority of models of AD in Drosophila have been
based on the expression of APP or Aβ. Although the Drosophila
genome encodes an APP ortholog, Appl, some critical elements
to the pathological signature of AD are not as obviously con-
served. Speciﬁcally, as reported in Section“Analysis of Invertebrate
Orthologs of AD Genes,” Drosophila Appl does not contain a
recognizable Aβ sequence and until recently no BACE ortholog
has been identiﬁed. However, Carmine-Simmen et al. (2009)
have recently identiﬁed a Drosophila BACE-like enzyme, dBACE.
Moreover, overexpression of dBACE and APPL results in the
production of a fragment containing the region in APPL that
corresponds to the Aβ peptide, which accumulates in neurotoxic
aggregates and induces age-dependent,AD-like behavioral deﬁcits
and neurodegeneration (Carmine-Simmen et al., 2009).
Many groups have also generated models of APP-mediated
AD-like pathologies in ﬂies by expressing transgenic constructs
of wild-type and FAD human APP, in the presence or absence
of other transgenes relevant to AD pathogenesis. For example,
co-expression of human wild-type APP and BACE together with
Drosophila Psn led to the production of Aβ peptides in ﬂies and
resulted in age-dependent neurodegeneration, accumulationofAβ
plaques and semi-lethality that could be suppressed by propagat-
ing the ﬂies onBACEor γ-secretase inhibitors (Greeve et al., 2004).
This phenotype could also be suppressed by loss of functionmuta-
tions in Psn, while co-expression with FAD-associated Psn trans-
genes enhanced the neurodegeneration phenotype (Greeve et al.,
2004), supporting an Aβ-related toxic gain of function for FAD-
associated mutations. Stokin et al. (2008) co-expressed human
FAD APP together with Drosophila FAD Psn in ﬂies and observed
increased levels of Aβ1−42 and enhanced amyloid deposition. Sur-
prisingly, despite the presence of increased levels of Aβ1−42, they
also observed suppression of the axonal transport defects and neu-
ronal apoptosis in ﬂies expressing FADAPP alone. This led them to
conclude that the APP-induced axonal defects were not due to Aβ
(Stokin et al., 2008).
Many groups have taken a more direct approach to study the
role of Aβ1−42 in the onset and progression of AD by directly
expressing theAβ1−42 peptides in ﬂy neurons. Importantly, unlike
most mouse models of Aβ, transgenic ﬂies expressing Aβ1−42
exhibit extensive cell loss, a difference that may be due to the
fact that Aβ accumulates intracellularly within neurons in ﬂies
whereas they are extracellular in most mouse models. While the
traditional clinical pathology of AD includes extracellular amy-
loid plaques, human AD brains show signiﬁcant accumulation of
intraneuronal Aβ1−42 (Takahashi et al., 2002). APP and Aβ1−42
expressing ﬂies can thus recapitulate many important aspects of
AD, including some phenotypes difﬁcult to model in the mouse
system, such as neuronal cell loss.
However, mutations in APP are a rare cause of FAD, with the
majority of FAD-associated mutations occurring within the PSEN
(Selkoe, 2001). Many groups have therefore sought to understand
the genetic and biochemical role that presenilins plays in the onset
and progression of AD. Drosophila models of presenilin-mediated
AD phenotypes have provided an increased understanding of the
role of presenilins in both development and disease. Mutations
in conserved residues of Drosophila Psn have been used to model
clinically heterogeneous human presenilins FAD mutations and
to assess their activity. Since several attempts to model AD in
ﬂies have focused on studying the role of tau in the generation of
NFTs, different groups have investigated the effect of expressing
wild-type or mutant tau in various ﬂy tissues.
Collectively these studies conﬁrm critical roles for presenilins,
APP, and Aβ1−42 in AD and demonstrate how Drosophila can be
used as an effective tool to understand the onset and progression
of AD-like phenotypes.
ZEBRAFISH TO MODEL ALZHEIMER’S DISEASE PATHOLOGY
The zebraﬁsh (Danio rerio) is rapidly emerging as a promising
model organism to study various CNS disorders, including AD.
Historically, rodent models have been used to study AD but addi-
tional animal models with complementary advantages must be
used to analyze the basis of the neurodegeneration and, subse-
quently, to evaluate the effects of novel drugs, as a previous step to
assays in rodents. Phenotypes of zebraﬁsh at different development
stages have been well-characterized, especially the development
of the nervous system (Kimmel et al., 1995). Zebraﬁsh offers a
reasonable compromise between physiological complexity and
throughput, has a fully characterized genome, and displays sig-
niﬁcant physiological homology to mammals, including humans
(Esch et al., 1990). Moreover, it presents a clear advantage in
comparison to other animal models: the larva–adult duality. The
availability of both forms is beneﬁcial and enables the investiga-
tionof awider spectrumof neurodegenerative-relatedphenomena
throughout ontogenesis.
The faster development and shorter lifespan of zebraﬁsh,
compared to mice, makes them and ideal choice to model devel-
opmental trajectories of neurodegeneration. Moreover, as rodent
models are expensive to maintain and more difﬁcult to modify
genetically, lower organisms emerge as useful species to increase
the knowledge of the mechanisms underlying neurodegenera-
tive processes. The zebraﬁsh is a vertebrate more closely related
to humans than invertebrate models such as yeast, worms, or
ﬂies (Guo, 2004). Although invertebrates can provide important
insights into neurodegeneration, the absence of a complex nervous
system limits their application in modeling intricate aspects of
CNSdisorders. Comparisonbetween various species is also impor-
tant for uncovering mechanisms associated to brain pathogenesis.
While the complementary use of zebraﬁsh could be an important
strategy for AD research, it represents an integral part of a more
global cross-species modeling (from ﬁsh to rodents) for uncov-
ering evolutionary conserved mechanisms of neurodegeneration.
Furthermore, zebraﬁsh has a short time of development to sexual
maturity (3 months) and a high reproductive rate (hundreds of
embryos per female per clutch and per week). Embryos are trans-
parent and developed externally, facts that allowdirect observation
of embryogenesis and development of the CNS. Embryos are also
easily amenable to methods for manipulating genes and protein
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activity such as injection of antisense oligonucleotides (Nasevicius
and Ekker, 2000; Eisen and Smith, 2008), mRNAs or transgenes,
and for screening of drug libraries being arrayed in microtiter
plates (Zon and Peterson, 2005). Moreover, whereas the early
zebraﬁshdevelopmental stages are likely to be important to analyze
CNS processes and abnormalities, adult ﬁsh with the full range of
brain functions should have a signiﬁcant advantage in the analysis
of the complex brain functions characteristics of vertebrates (Pan-
ula et al., 2006), and in the studies of conductual phenotyping.
Indeed, zebraﬁsh exhibit many higher order behaviors including
memory, conditioned responses, and social behaviors like school-
ing (Lieschke andCurrie, 2007). All these properties strengthen the
zebraﬁsh as an ideal model for studying human diseases, including
CNS disorders (Grunwald and Eisen, 2002). As reported before,
one important advantage of the zebraﬁsh is the genome organiza-
tion and the genetic pathways controlling signal transduction and
development, because they are highly conserved between zebraﬁsh
and vertebrates (Postlethwait et al., 2000). Indeed, the zebraﬁsh
genes share 50–80% homology with most human sequences and
several genome databases similar to mouse have been generated.
For these reasons, transgenic zebraﬁsh are continuously increasing
in number and being used to model human diseases.
Two orthologs of APP, appa and appb have been identiﬁed in
zebraﬁsh. Both genes have approximately 70% amino acid iden-
tity to human APP695, with 80% identity in the Aβ1−42 region
and 95% identity within the transmembrane domain (Musa et al.,
2001). The expression pattern of these two genes is similar to
that observed for the mouse APP695 isoform (Sarasa et al., 2000).
This indicates that APP gene function is conserved during verte-
brate evolution. Regarding to APP zebraﬁsh models, Lee and Cole
(2007) used the zebraﬁsh appb promoter to express green ﬂuo-
rescent protein (GFP) in transgenic animals. This model revealed
that appb is mainly expressed in sub regions of brain, spinal cord,
and the developing vasculature of the zebraﬁsh embryos. More-
over, in adult transgenic zebraﬁsh, appb was abundantly expressed
in the brain (telencephalon, optic tectum, thalamus, and cerebel-
lum; Lee and Cole, 2007). The demonstration that zebraﬁsh appb
gene regulatory elements can be used to drive GFP expression in
both embryos and adults will be important for future studies that
focus on expressingmutant humanAPP in zebraﬁsh. In this study,
the authors predicted that zebraﬁsh expressing mutant human
APP will generate Aβ plaques, although did not demonstrate their
presence. In other study, Joshi and coworkers knocked down the
zebraﬁsh appa and appb function by morpholino (MO) injection
resulting in a shortened body axis, a short, curly tail, mild synoph-
thalmia, and defective convergent-extension movements during
gastrulation (Joshi et al., 2009). Injecting appa-MO showed no
or mild defects in developing embryos whereas appb-MO caused
phenotypic changes similar to those observed when both MOs
were injected together. These defects can be rescued by human
APP695 mRNA, partially rescued by human sAPPα mRNA, but
cannot be rescued by APP bearing the Swedish mutation (APPswe;
(Joshi et al., 2009). These data suggest that APP processing plays
an important role in APP function and that APPswe is functionally
deﬁcient and thepossibility thatAPPswe maynot only contribute to
AD pathogenesis during aging but also may exert changes during
embryonic development.
Despite conservation of the Aβ domain and of the secretases
between zebraﬁsh and humans, a zebraﬁsh Aβ peptide has not
yet been found and it is not known if the above posttranslational
modiﬁcations that occur in human APP processing also occur in
zebraﬁsh.
Zebraﬁsh embryos are a valuable system in which to study
presenilins function. Orthologs of PSEN1 and PSEN2 have been
identiﬁed in zebraﬁsh (psen1 and psen2). Sequence alignment of
zebraﬁsh and human presenilins protein sequences displays these
primary structures as being highly conserved, though there are
highly variable regions at the N-terminus and the C-terminal
half of the cytoplasmic loop domains. Transcripts from zebraﬁsh
psen1 are ubiquitously expressed from fertilization in the zebraﬁsh.
Zebraﬁsh psen2 mRNA is present from fertilization but protein
expression has only been detected from the onset of gastrulation
(6 h post fertilization). By modulating presenilins expression, it is
possible to elucidate its function and regulation in zebraﬁsh.
Regarding the tau zebraﬁsh models recent developments
strengthen the zebraﬁsh as a model for the study of tauopathies
(Bai and Burton, 2011) also because the zebraﬁsh genome con-
tains highly conserved orthologs of each of the kinases implicated
in tau phosphorylation (Bai et al., 2007).
Todate, themain genetic risk factor associatedwith the sporadic
form of AD is the allele 4 of the APOE gene (APOE-ε4; Corder
et al., 1993; Saunders et al., 1993). A zebraﬁsh gene ortholog to
mammalian APOE has been previously identiﬁed (Durliat et al.,
2000) but APOE zebraﬁsh transgenic models have not yet been
developed. For a summary of advantages and disadvantages of
vertebrate and invertebrate models see Figure 3.
RODENT MODELS OF ALZHEIMER’S DISEASE
The mouse was the ﬁrst organism in which transgenic technology
and gene targeting became widely available. Mice offer several
advantages in scientiﬁc research: they are small and easy to rear,
their progeny are abundant and gestation very short and last, but
not least, their genome was whole mapped. A valid animal model
forAD should exhibit progressive disease-like neuropathology and
cognitive deﬁcits; reliable models should manifest little cognitive
deﬁcits until a certain advanced age and then should ideally display
progressive impairment of speciﬁc memory system while other
memory systems are saved.
A mouse model that recapitulates all the aspects of AD has not
yet been produced, even if each model allows for in-depth analysis
of one or two components of the disease, which is not readily
possible or ethical with human patients or sample.
TRANSGENIC ALZHEIMER’S DISEASE MODELS
In light of the importance of creating a reliable AD model, several
transgenicmice lines were generated. Thesemodels should be able
to discern pathogenic effects of familiar mutations from those of
transgene overexpression (Janus andWestaway, 2001).
Since 1993, numerous knockout animals have been devel-
oped to explore a particular aspect of AD: suppression of genes
that encode proteins involved in the pathogenesis has helped
to anticipate the effects of presumptive new molecules designed
to regulate these protein. Knockout mice have been made not
only of the APP, secretases, i.e., BACE, PSEN1 and 2, ADAM10
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FIGURE 3 | Schematic representation of advantages and disadvantages of the use of the vertebrate and invertebrate models of AD.
(Shen et al., 1997; Herreman et al., 1999; Luo et al., 2001; Hart-
mann et al., 2002; Lee et al., 2003), but also of both APP and
tau protein, proving invaluable in understanding disease progres-
sion and in identifying physiological roles for the APP protein
(Zheng et al., 1996; Takei et al., 2000). Presenilin knockout mice
developed striking neurodegeneration of cerebral cortex, impair-
ment of memory and synaptic function, which call for caution
in the therapeutic use of γ-secretase inhibitors (Shen et al., 1997;
Saura et al., 2004). BACE is the exclusive β-secretase enzyme, and
its activity is also crucial for the production of Aβ. Although
its physiological functions were unclear, this enzyme has been
object of inhibitor program; β-secretase knockout mice are per-
fectly viable with no obvious defects and no longer produced
any Aβ (Luo et al., 2001; Roberds et al., 2001). In 2006, Hu and
Willem reported that BACE knockout mice showed signiﬁcantly
reduced level of myelination and myelin thickness (Hu et al.,
2006; Willem et al., 2006), suggesting an important role of this
enzyme in the development of the nervous system. Furthermore,
BACE has a large active site, which makes difﬁcult to ﬁnd com-
pounds that cross blood–brain barrier and are large enough to
inhibit the active site without being hydrolyzed by endopeptidase
(Huang et al., 2009).
Current transgenic models of AD rely on information gathered
from inherited forms of the disease, far less common than spo-
radic ones but indistinguishable from a clinical histopathological
point of view. Aﬁrst attempt to generate transgenicmodel counted
only on overexpression of entire sequence of human APP770 gene
(Buxbaum et al., 1993; Lamb et al., 1993), human APP751 (Quon
et al., 1991; Moran et al., 1995), human APP695 (Yamaguchi et al.,
1991), and Aβ (Wirak et al., 1991) in the brain. Despite APP trans-
gene was successfully expressed in the brain, these models did
not provide evidence of plaque deposition in most cases, and dis-
played very mild neuropathological changes. The lack of plaques
in these transgenic mice was generally attributed to insufﬁcient
levels of the transgene, to the absences of a disease-causing muta-
tion in the transgene, to the genetic background of mice or to
other unknown factors inherent to the mouse brain, compared
to human. The ﬁnding that besides its overexpression APP must
be also mutated for the production of high levels of Aβ led later
to generation of new animal models; these mice developed age-
dependent AD-like pathology including amyloid deposit in brain
parenchyma (Hsiao et al., 1996; Moechars et al., 1999). Of the
more than 20 autosomal dominant APP mutations linked to AD
that appear to enhance the aggregation of Aβ, only few muta-
tions have been used to generate transgenic mice: V717I “London”
mutation (Goate et al., 1991), V717F “Indiana” mutation (Mur-
rell et al., 1991), K670D/M671L“Swedish”mutation (Mullan et al.,
1992), and E693G “Artic”mutation (Nilsberth et al., 2001).
However, transgenic mice do not develop extensive neuronal
loss, like human AD patients. This can be ascribed to the amount
of time needed: in humanADprogresses over decades while trans-
genic mice are kept only for 2 years. Another problem may be
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related to background strains: (i) the most used mice strain is
C57BL/6 which may be more resistant to excitotoxicity, (ii) the
heterogeneity of humans is more complex compared with inbred
mouse strains, (iii) fundamental differences between mice and
humans exist (LaFerla and Green, 2012).
Here we report a description of the main characteristics of the
most used transgenic mice to reproduce AD.
PDAPP mice
Report of the ﬁrst transgenic mouse able to develop a robust AD-
related phenotype was pub lished in 1995 (Games et al., 1995).
This line [known as PDAPP (PDGF-hAPP), Figure 4A] overex-
presses human APP with “Indiana” mutation under the control
of platelet-derived growth factor beta (PDGF-β) promoter on
a mixed C57BL/6, DBA, and Swiss-Webster strain background,
which leads to a 10-fold elevation of APP sufﬁcient to gener-
ate Aβ for extracellular plaques. The PDGF-β promoter targets
expression preferentially to neurons in the cortex, hippocampus,
hypothalamus, and cerebellum of the transgenic animals. The
PDAPP model was the ﬁrst transgenic mouse to overexpress the
human APP that successfully recapitulated several neuropatho-
logical features characteristic of AD: Aβ deposition in both diffuse
and neuritic plaques, cerebral amyloid angiopathy (CAA), astro-
cyosis, microgliosis, hippocampal atrophy, synaptic alterations,
and behavioral deﬁcits (Dodart et al., 1999). Many of the histo-
logical, biochemical, and structural alterations of PDAPP mouse
closely resemble the changes found in the brain of AD patients,
especially the temporal and spatial-speciﬁc deposition of Aβ in
the brain. The animals, however, did not develop tauopathy or
signiﬁcant neuronal cell death (Irizarry et al., 1997b). At 3 month
of age the transgenicmice displayed signiﬁcant hippocampal atro-
phy, while at 4–5 months of age showed an enhanced paired-pulse
facilitation (PPF), distorted responses to high frequency stim-
ulation bursts, and long-term potentiation (LTP) decays more
rapidly (Larson et al., 1999). In heterozygotic mice, between
4 and 6 months of age, no obvious pathology was detected;
however, at ∼6–9 months of age, transgenic animals began to
exhibit deposits of human Aβ in the hippocampus, corpus callo-
sum, and cerebral cortex, but not in other brain regions. These
increased with age, and by 8 months, many deposits were seen.
At age >9 months, the density of the plaques increased until the
Aβ-staining pattern resembled that of AD. By 18 months, they
produced neuritic alterations and gliosis without widespread neu-
ronal death (Irizarry et al., 1997b; Johnson-Wood et al., 1997). The
PDAPP mouse has proven to be an attractive model to study the
disease process underlying aspects of AD that are related to Aβ
aggregation and its consequences. Although this model developed
amyloid deposits, it failed to meet all criteria of the neuropathol-
ogy of human AD in the absence of cortical or hippocampal
neuronal loss or NFTs in aged transgenic animals (Irizarry et al.,
1997a). The PDAPP mouse has been extensively used to study the
effect of genetic factors that modify AD, as well as Aβ-binding
proteins and their effect on Aβ deposition (Brendza et al., 2002).
Tg2576 mice
In 1996, a second line (Tg2576, Figure 4B), created by Hsiao
et al. (1996), also made sufﬁcient Aβto form deposits, and, in
addition, this mouse showed age-related cognitive impairment.
Human APP695 containing the double mutation Lys670->Asn,
Met671->Leu (Swedish mutation), was inserted into B6;SJL F2
mice using a hamster prion protein cosmid vector. The resul-
tant transgenic mice were bred to C57BL/6 mice. The colony was
maintained by mating hemizygotes to B6SJL F1 mice. Transgenic
mice 11–13 months of age show a 14-fold increase in Aβ1−42/43
over those at 2–8 months of age. The elevated Aβ levels are
associated with the development of amyloid deposits in frontal,
temporal, and entorhinal cortex (EC), hippocampus, presubicu-
lum, subiculum, and cerebellum (Hsiao et al., 1996). Nine to ten
month old Tg2576 mice demonstrate memory deﬁcits in Y mazes
and Morris water maze (MWM) behavioral tests. These behav-
ior alterations correlate with the development of amyloid plaques
and with impaired LTP in both the CA1 and dentate gyrus regions
of the hippocampus (Chapman et al., 1999). These transgenic
mice also show a signiﬁcant microglial response to the amyloid
plaques with an increase in both number and area (Frautschy
et al., 1998). Although several groups have described cognitive
decline with the appearance of senile plaques (Chen et al., 2000;
Janus et al., 2000; Gordon et al., 2001), deep cognitive investiga-
tion into Tg2576 mice over a broader age range (4–22 months),
failed to show any overall correlation between memory func-
tion and insoluble Aβ levels, although correlation was observed
within individual age groups (Westerman et al., 2002). Charac-
terization of the timing and nature of preplaque dysfunction is
important for understanding the progression of this disease and
to identify pathways and molecular targets for therapeutic inter-
vention. Examination of the progression of dysfunction at the
morphological, functional, and behavioral levels in the Tg2576
mouse model of AD, shows that decreased dendritic spine den-
sity, impaired LTP, and behavioral deﬁcits occurredmonths before
plaque deposition, which was ﬁrst detectable at 18 months of
age (Jacobsen et al., 2006). As for PDAPP model, Tg2576 mice
do not exhibit neuronal loss despite having extensive amyloid
deposition (Irizarry et al., 1997b).
APP23Tg mice
Another mouse model similar to Tg2676 is APP23Tg mouse
(Figure 4C). Thismice linewas constructed on aC57BL/6//DBA/2
genetic background (Andra et al., 1996); human APP751 with
Swedish mutation was insert under control of Thy-1.2 promoter.
Mice have a sevenfolds overexpression of APP and ﬁrst show
Aβ deposits at 6 months of age (Sturchler-Pierrat et al., 1997).
Deposits increase with age in size and number and eventually
occupy a substantial area of the neocortex and hippocampus
in 24 months old mice. Associated with the amyloid, there are
inﬂammatory reactions, neuritic and synaptic degeneration as
well as tau hyperphosphorylation. The plaque cores are substan-
tially more soluble than those in the AD brain. The mice show
more congophilic plaque, high levels of Aβ in cerebrospinal ﬂuid,
and regional localization of CAA (Winkler et al., 2002). Cere-
bral amyloidosis is not sufﬁcient to account for global synapse
loss in AD (Boncristiano et al., 2005). Behavioral characteriza-
tion was done at 3, 18, and 25 months of age (Kelly et al.,
2003); in passive avoidance APP23Tg mice were unimpaired up
to 25 months of age and, in spatial memory performance in the
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FIGURE 4 | Continued
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FIGURE 4 |Time-line of the main features of transgenic mice. (A) PDAPP
mice overexpress human APP transgene containing the Indiana mutation
(V717F) under the control of the PDGF-β promoter; (B)Tg2576 mice
overexpress human APP695 transgene containing the Swedish mutation
(APPK670/671L) under the control of the hamster prion protein promoter;
(C) APP23Tg mice overexpress human APP751 transgene containing the
Swedish mutation (APPK670/671L) under the control of Thy-1.2 promoter;
(D) CRND8Tg mice overexpresses human APP695 transgene containing the
Swedish (APPK670/671L) and Indiana mutation (V717F), under the control of
Syrian hamster PrP promoter; (E)Tg2576 mice were crossed with Tg A246E
mice (expressing a mutant human PSEN1 gene), under the control of the
mouse prion protein promoter; (F)Tg2576 was crossed with mice expressing
human PSEN1-M146L mutant, under PDGF promoter; (G)TASTPM mice
express human APP with Swedish mutation (APPK670/671L) and PS1-M146V
mutation, underThy-1 promoter; (H) APPswe/PSEN1dE9 mice express human
APP with Swedish mutation (APPK670/671L) and PSEN1 with exon 9
deletion, under mouse PrP promoter; (I) 3xTg mice: in this model human
APP695 cDNA harbouring the Swedish mutation (KM670/671NL) was
subcloned into exon 3 of theThy1.2 expression cassette. Human four-repeat
tau without amino terminal inserts (4R0N) harbouring the hP301L mutation
was also subcloned into Thy1.2 expression cassette. The two were
comicroinjected into the pronuclei of single-cell embryos harvested from
homozygous PSEN1-M146V knockin mice; (L) APPswe/TAUvlw mice
areobtained by crossingTg2576 mice andTAUvlw mouse lines expressing
human 4-repeat tau containing a triple mutation (G272V, P301L and R406W)
and both gene are under control of hamster PrP promoter; (M)
pR5/APP/PSEN2 triple transgenic: APPswePSEN2N141I double transgenic
mice were crossed with P301L tau transgenic pR5 mice
MWM test, the mice show age-dependent learning deﬁcits and
poor memory. Deﬁcits in spatial memory and spatial working
memory were found already at 3 and 6 months of age, when
there was no plaque deposition (Van Dam et al., 2003). As in
AD, no deposits are found in the cerebellum, but a consider-
able amount of vascular amyloid is detected. This is particularly
noteworthy, because APP expression is restricted to neurons
(BornemannandStaufenbiel, 2000). All deposits show immunore-
activity with a number of different Aβ antibodies, which is
comparable to the staining of brain sections from AD patients.
The Aβ deposits also react with end-speciﬁc antibodies recogniz-
ing the amino terminus of Aβ or its carboxy termini at amino
acids 40, 42, and weakly at 43 (Paganetti et al., 1996). Biochemical
analyses of brain cortex lysates showed that the Aβ1−40 form
is a little more prominent than the Aβ1−42 form. However,
the amount of both Aβ1−40 and Aβ1−42 exponentially increases
during aging in parallel to the increase in plaque volume, whereas
the APP level remains constant (Bornemann and Staufenbiel,
2000).
CRND8Tg – TgJ9 – TgJ20 mice
In 2001, a transgenic line of the earliest-onset AD, that develops
plaque as early as 3 months, was generated. These mice, named
CRND8Tg, carry both the Swedish and Indiana mutation, and
the human APP695 is under the control of Syrian hamster PrP
promoter (Chishti et al., 2001). Expression of mutant APP is
about ﬁvefold than endogenous murine APP, and due to a rapid
increase in the Aβ1−42/Aβ1−40 ratio, CRND8Tg develop a very
aggressive pathology with a high mortality. To detect cognitive
deﬁcits different behavioral tests were carried out; in MWM
(Chishti et al., 2001), fear conditioning (Greco et al., 2010), audi-
tory startle, and prepulse inhibition (McCool et al., 2003) mice
show impairments in reference, recognition, working, and spatial
memory (Figure 4D).
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Two others transgenic mice similar to CRND8Tg were gener-
ated: TgJ9 and TgJ20. These lines express both the Swedish and
Indianamutation on the humanAPP770 isoform under control of
PDGF promoter. Unlike CRND8Tg, the pathology is less aggres-
sive, in fact TgJ9 and TgJ20 show plaques deposition occurring
at 8–10 months of age in the dentate gyrus and in the neocor-
tex, furthermore expression of Aβ is low in TgJ9 mice rather than
TgJ20 (Mucke et al., 2000; Chin et al., 2005). Although all trans-
genic mice described above do not recapitulate a complete picture
of the neuropathology of ADdue to absence of NFTs, neurodegen-
eration and cerebral atrophy, each model shows anatomical and
morphological pattern of plaques formation similar to that seen
in human AD.
Double transgenic mice
As for APP, mutations in presenilin are involved in FAD. To deter-
mine the effects of PSEN1 on APP processing, both wild-type and
mutant presenilin 1 transgenic mice have been created (Duff et al.,
1996). Transgenic mice expressing either a wild-type or mutated
presenilin gene fail to develop signiﬁcant AD-like pathology,
despite having intra- but not extracellular Aβ deposition (Borchelt
et al., 1996; Duff et al., 1996; Chui et al., 1999). These properties
have prompted a number of studies into the characteristics of
mice expressing the human versions of presenilins and of APP.
To accelerate plaque deposition in transgenic line of AD, multiple
PSEN1 and APP mutations were inserted in mice. Tg2576 mice
were crossed with mice expressing a mutant human PSEN1 gene
(Tg A246E); the mouse prion protein promoter directs expression
of both transgenes. Elevated levels of the Aβ1−42/43 peptides are
detected in brain homogenates. By 9 months of age, histological
examination of brain tissue reveals numerous amyloid deposits
resembling those observed in the brains of AD patients. The num-
ber of amyloid deposits increases dramatically between the ages of
10 and 12months (Figure 4E). These mice provide a useful model
for studying the underlying mechanism of amyloid deposition, a
process implicated in AD (Borchelt et al., 1998).
WhenTg2576was crossedwithmice expressinghumanPSEN1-
M146L mutant under PDGF promoter, generating the PSAPP
transgenic line (Figure 4F; Holcomb et al., 1998), plaque depo-
sition occurred at 8–10 weeks compared to 8–12months for single
APP-mutated mice (McGowan et al., 1999; Kurt et al., 2001). Fur-
thermore, double transgenicmice revealed a selective 41% increase
in Aβ1−42/43 in homogenate of their brain. This model shows
cognitive impairments due to loss of reference, working, spa-
tial and recognition memory, and in addiction is characterized
by astrogliosis, microgliosis and dystrophic neuritics (Holcomb
et al., 1998). Another mouse model with the same histopatholog-
ical characteristics of PSAPP is the TASTPM mouse (Figure 4G)
that expresses human APP with Swedish mutation and PSEN1
with M146V mutation under Thy-1 promoter (Howlett et al.,
2004, 2008). Plaque depositions are visible at 3 months of age
and are composed of Aβ1−42 and Aβ1−40 with compact struc-
ture in cortical and hippocampal areas and localized neuronal cell
loss (McGowan et al., 1999; Howlett et al., 2004). Single mutation
insertion is not the only strategy used to manipulate PSEN1 gene;
PSEN1with deletion at exon 9was co-expressed withAPP Swedish
mutant undermousePrPpromoter to generateAPPswe/PSEN1dE9
(Lee et al., 1997). In this transgenic mice plaques appear less dense
as in human pathology and have been found cognitive deﬁcits
in spatial and recognition memory (Howlett et al., 2004; Garcia-
Alloza et al., 2006; Dinamarca et al., 2008). Spatial reference
memory was assessed in a standardMWM task followed by assess-
ment of episodic-like memory in Repeated Reversal and Radial
Water maze tasks. At 6 months of age, APPswe/PSEN1dE9 double-
transgenic mice showed visible plaque deposition (Figure 4H);
however, all genotypes, including double-transgenic mice, were
indistinguishable from non-transgenic animals (Savonenko et al.,
2005). In the 18-month-old cohorts, amyloid burdens were much
higher in APPswe/PSEN1dE9 mice with statistically signiﬁcant but
mild decreases in cholinergic markers (cortex and hippocampus)
and somatostatin levels (cortex; Savonenko et al., 2005). Some
forms of Aβ associated with amyloid deposition can disrupt cog-
nitive circuits when the cholinergic and somatostatinergic systems
remain relatively intact.
Tau pathology and triple transgenic mice
One of the limit of the transgenic mice described above, is the
lack of NFTs even though the tau protein is present in hyper-
phosphorylated form. To exceed this, mice lines with mutations
in tau protein or triple transgenic mice were created. In (Oddo
et al., 2003b) generated a triple transgenic line (3xTg, Figure 4I):
human APP695 cDNA harboring the Swedish double mutation
(KM670/671NL) was subcloned into exon 3 of the Thy1.2 expres-
sion cassette. Human four-repeat tau without amino terminal
inserts (4R0N)harboring thehP301Lmutationwas also subcloned
into Thy1.2 expression cassette. The two were co-microinjected
into the pronuclei of single-cell embryos harvested from homozy-
gous PSEN1-M146V knockin mice (Oddo et al., 2003b). 3xTg
mice develop an age-related and progressive phenotype includ-
ing plaques and tangles. Synaptic dysfunction, including LTP
deﬁcits, manifests in an age-related manner, but before plaque
and tangle pathology. Deﬁcits in long-term synaptic plasticity cor-
relate with the accumulation of intraneuronal Aβ (Oddo et al.,
2006; Pietropaolo et al., 2008). Hippocampus and cerebral cor-
tex contained highest steady-state levels of APP and Tau proteins
and extracellular Aβ deposits ﬁrst appear in 6-month-old mice
in the frontal cortex, and were readily evident by 12 months.
There is a progressive increase in Aβ formation as a function
of age in the 3xTg brains and a particularly pronounced effect
on Aβ1−42 levels (Oddo et al., 2003a). The mice develop cog-
nitive impairments by 4 months of age. The ﬁrst impairments
manifest as a retention/retrieval deﬁcit and not as a learning
deﬁcit, and occur prior to the occurrence of any plaque or tangle
pathology. The mice show deﬁcits on both spatial and contex-
tual based paradigms and this early cognitive deﬁcits can be
reversed by immunotherapy (Oddo et al., 2004; Billings et al.,
2005). Others transgenic lines with tau pathology were made;
Tg2576 mice were crossed with tauvlw mouse lines expressing
human 4-repeat tau containing a triple mutation (G272V, P301L,
and R406W) and both gene are under control of hamster PrP pro-
moter (Figure 4L). The double transgenic mouse APPswe/tauvlw
(Perez et al., 2005) showed enhanced amyloid deposition accom-
panied by neuroﬁbrillary degeneration and overt neuronal loss
in selectively vulnerable brain limbic areas. Not only resulted in
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increased tau phosphorylation but also triggered NFT-like forma-
tion were observed in the EC and CA1 regions at 25 months of
age (Ribe et al., 2005). Fivefold higher amyloid burdens appeared
in APPswe/tauvlw female mice in comparison to male mice. Co-
expression of human mutant APP and tau in the APPswe/tauvlw
mousemodel enhancedbothADand taupathology and resulted in
signiﬁcant neuronal loss in selective vulnerable brain areas. Learn-
ing andmemory deﬁcits, asmeasured by theMWMtest,were quite
modest at 9 months of age despite incipient amyloid deposits in
APPswe/tauvlw and APPswe brains, and signiﬁcant neuronal loss
in the EC in the former. By 16 months, however, both APPswe
and APPswe/tauvlw mice showed marked spatial reference mem-
ory impairment compared to tauvlw and non-transgenic littermate
controls (Perez et al., 2005; Ribe et al., 2005).
Recently a new triple transgene line was generated:
APPswePSEN2-N141I double transgenic mice were crossed with
P301L tau transgenic pR5 mice giving raise to pR5/APP/PSEN2
triple transgenic mice (Rhein et al., 2009; Figure 4M). This new
model shows age-dependent accumulation of Aβ plaques and
NTFs in the cortex, hippocampus and amygdala with no mea-
surable cell loss at 16 months (Rhein et al., 2009; Grueninger et al.,
2010).
TgF344-AD RAT MODEL
Recently Cohen et al. (2013) have generated a transgenic ratmodel
(TgF344-AD) expressing human APP with Swedish mutation and
PSEN1 deleted in exon 9 (PSEN1E9). The human genes, driven
by mouse prion promoter, were co-injected in rat pronuclei on a
Fischer344background. TgF344-ADrats expressed 2.6-foldhigher
human holo- and secreted APPSWE proteins than endogenous rat
APP and 6.2-fold increased human PSEN1E9 protein versus
endogenous rat protein. The model manifests progressive age-
dependent Aβ deposition not only in the hippocampus but also
in the striatum and cerebellum. The authors have also assessed
cognitive performance in the Barnes maze, a widely accepted
test for hippocampus-dependent spatial reference learning and
memory in rat (Barnes, 1979; Barnes et al., 1994); they found
that 15-month-old Tg animals made signiﬁcantly more errors
during the learning phase versus 6-month-old Tg or wild-type
animals. Moreover, Tg rats showed age-dependent abnormali-
ties in open ﬁeld activity and spatial learning memory. Unlike
the transgenic mice that show tau pathology only when they
harbor the mutated tau gene (Oddo et al., 2003b; Rhein et al.,
2009), the TgF344-AD line manifests tauopathy relying solely on
endogenous rat tau protein. Finally, Tg rats show consistent and
extensive neuronal loss in cortical andhippocampal regions and an
age-dependent trend toward decreased hemispheric brain weight
(Cohen et al., 2013). In conclusion this model recapitulates all
aspects of AD pathology and represents a starting point for a next-
generation animal model to enable basic and translational AD
research.
NON-TRANSGENIC MICE MODELS OF ALZHEIMER’S DISEASE
None of the available models has helped to reach a comprehensive
explanation of the origin of the disease, especially regarding spo-
radic LOADand the complexity of its etiology. For this reason, new
hypothesis on the origin of the disease and their corresponding
animal models are blooming. For instance, loss of function of
presenilin has been claimed to explain both FAD and sporadic
LOAD (Shen and Kelleher, 2007) and other processes, such the
relation between ApoE4 and cholesterol metabolism or the role
of cholesterol, have been proposed as causative rather than pro-
gression factors in the pathological cascade. Published data show
that senescence-accelerated mouse (SAMP8), a model of aging,
displays many features that are known to occur early in the
pathogenesis of the disease such as increased oxidative stress, Aβ
alterations and tau phosphorylation (Tomobe andNomura,2009).
Therefore, SAMP8 mice may be an excellent model for studying
the earliest neurodegenerative changes associated with sporadic
LOAD and provide a more encompassing picture of human dis-
ease, a syndrome triggered by a combination of age-related events
and not-completely known risk factors.
Starting from the consideration that cerebral glucose
metabolism abnormalities have been found in AD (Hoyer, 1992),
models of AD-type neurodegeneration in adults rats were gen-
erated treating animals with intracerebroventricular injection of
Streptozotocin (icv-STZ), a glucosamine–nitrosourea compound
which generates a cytotoxic product whenmetabolized and causes
oxidative stress, DNA damage, and diabetes mellitus, even if the
mechanismof cytotoxicity is unknown (Plaschke andHoyer, 1993;
Duelli et al., 1994; Lester-Coll et al., 2006; Plaschke et al., 2010).
The treatment causes chronic reduction in glucose and glycogen
metabolism in the cerebral cortex and hippocampus (Plaschke
and Hoyer, 1993) and these effects are associated with signiﬁcant
inhibition of insulin receptor function and progressive deﬁcits
in learning, memory, cognitive behavior, cerebral energy balance
(Lannert and Hoyer, 1998; Hoyer and Lannert, 1999; Hoyer et al.,
2000). Moreover, the treatment of rat pups with icv-STZ injection
showed an alteration of insulin and insulin-like growth factor sig-
naling mechanisms in the brain, an increase of phopsho-tau and
extracellular plaque-like deposit of Aβ (Lester-Coll et al., 2006).
Recently, the role of insulin resistant brain state (IRBS) was eval-
uated in genetic mice models of AD (Plaschke et al., 2010). Six
months after icv-STZ treatment, nine-month-old Tg2576 mice
were investigated: they showed an increase of mortality, reduc-
tion of spatial cognition, increase of cerebral aggregated Aβ40−42
fragments, total tau protein and congophilic amyloid deposits
compared with mice treated with placebo (Plaschke et al., 2010).
The authors showed for the ﬁrst time that AD-like functional and
structural changes in Tg2576 mice are aggravated by IRBS caused
by icv-STZ injection, and these data support the concept that AD-
type neurodegeneration represents an intrinsic neuroendocrine
disease (Lester-Coll et al., 2006; Plaschke et al., 2010).
Another way to mimic AD is to perform icv injection of solu-
ble Aβ1−42 (icv-Aβ) since it induces synaptotoxicity and memory
dysfunction (Hardy and Selkoe, 2002), and several groups stud-
ied the effects on different pathways. Canas et al. (2009) showed
that icv-Aβ caused a delayed loss of memory performance that
was selectively associated with loss of synaptic markers without
neuronal damage nor astrogliosis/microgliosis. Moreover, they
demonstrated that blockade (pharmacologic or genetic) of adeno-
sine A2A receptor (A2AR) can prevent this effect through a
mechanism involving the control of p38 mitogen-activated pro-
tein kinase pathway. Lee et al. (2012) demonstrated that icv-Aβ
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in mice induced neuronal cell death in the hippocampal CA1
region, microglia and astrocyte activation, nitrotyrosine forma-
tion, inducible nitric oxide synthase expression, and memory
impairment.
Even if these models do not recapitulate all the aspects of AD,
theymight be useful to study the different pathways affected inAD
pathology, leading to the identiﬁcation of potential therapeutic
strategies.
In this scenario, it is fundamental to generate new hypothesis.
Recently, Kim et al. (2009) reported two potentially pathogenic
mutations with incomplete penetrance for LOAD in the gene for
the α-secretase ADAM10. It was already known that ADAM10
interacts directly with synapse-associated protein 97 (SAP97), a
cargo protein involved in trafﬁcking of glutamate receptors to the
postsynaptic density. This interaction is required for ADAM10
localization at postsynaptic membranes and for its enzymatic
activity (Marcello et al., 2007). As a consequence, interfering with
ADAM10/SAP97 complex in rodents can reduce ADAM10 local-
ization and activity on APP at synaptic membrane. This shifts
APP metabolism toward amyloidogenesis. Given the identiﬁca-
tion of ADAM10 as a candidate AD susceptibility gene, interfering
with its trafﬁcking and with its activity could represent a new
potential pathogenic mechanism that should be investigated in
minute details in new natural mousemodels. To this, we described
an innovative, non-transgenic animal model of AD (Epis et al.,
2010). This model mimics early stages of sporadic disease, which
represents the vast majority of cases. The model was obtained
by interfering with the complex ADAM10/SAP97 for 2 weeks by
means of a cell-permeable peptide strategy. This is sufﬁcient to
shift the metabolism of APP toward amyloidogenesis and allows
the reproduction of initial phases of sporadic AD (Figure 5).
After 2 weeks of treatment, we detected progressive AD-like neu-
ropathology, with an increase of Aβ aggregate production and of
tau hyperphosphorylation, and a selective alteration of N-methyl-
D-aspartic acid receptor subunit composition in the postsynaptic
compartment of mouse brain. Behavioral and electrophysiolog-
ical deﬁcits were also induced by peptide treatment. Despite the
important achievements obtained through transgenic mice, iden-
tifying the earliest possible mechanisms that induce evidence of
neuropathology, before signs of functional deﬁcits emerge, is now
seen as a need. In this way, the most vulnerable neurons could be
identiﬁed, new disease mechanisms could be investigated and a
means of reﬁning novel treatments would be provided. And even-
tual discrepancies and similarities between future models should
not disqualify or diminish the importance of any mouse model
but rather should stimulate more reﬁned comparison.
FUTURE PERSPECTIVES
MODELING ALZHEIMER’S DISEASE IN CELLULAR SYSTEMS
Generation of human induced pluripotent stem cells (iPSCs) pro-
vides a new method for elucidating the molecular basis of human
disease (Takahashi et al., 2007; Yu et al., 2007). An increasing
number of studies have employed disease-speciﬁc human iPSCs
in neurological diseases, and some of them have demonstrated
disease-speciﬁc phenotypes to model the neurological phenotype
(Dimos et al., 2008; Park et al., 2008; Ebert et al., 2009; Lee et al.,
2009; Soldner et al., 2009; Chamberlain et al., 2010; Ku et al., 2010;
Marchetto et al., 2010; Nguyen et al., 2011). The idea of studying
AD with iPSCs initially seems counterintuitive. Taking a cell type
that mimics the earliest stages of human development and expect-
ing these cells to inform one about a disease that typically afﬂicts
people over the age of 65 does initially seem at odds with our
basic understanding of AD. APP, presenilin, and APOE transgenic
and knockout mouse models have clearly taught us a great deal
about the function of these genes and their role in AD pathogen-
esis. However, it is reasonable to conclude that genetic differences
between humans and mice have also contributed to our difﬁcul-
ties in accurately modeling AD and generating clinically predictive
data. Human stem cell-based models may therefore provide an
alternative approach to clarify both the normal and pathogenic
roles of AD-associated genes. Patient-derived iPSCs have been
used tomodel a growing list of human genetic disorders (Grskovic
et al., 2011).
Most recently, two groups have reported the establishment and
investigation of AD iPSCs (Yagi et al., 2011; Israel et al., 2012). In
one study, Yagi et al. (2011) generated iPSC from ﬁbroblasts of
FAD with the PSEN1 mutation A246E and the PSEN2 mutation
N141I, and reported the differentiation of these cells into neurons.
They demonstrated that patient-derived differentiated neurons
show increased Aβ1−42 secretion, recapitulating the pathologi-
cal mechanism of FAD with PSEN1 and PSEN2 mutations. Their
ﬁndings demonstrated that the FAD–iPSC-derived neuron is a
valid model for studying AD, and provides important clues for
the identiﬁcation and validation of candidate drugs. In a sec-
ond study, Israel et al. (2012) generated iPSCs from not only FAD
patients but also two cases of sporadic AD and two unaffected
controls. Interestingly, neurons derived from one of the spo-
radic AD cases mimicked some of the ﬁndings from FAD cases;
showing increased Aβ1−40 generation and tau phosphorylation,
activation of glycogen synthase kinase-3b, and accumulation of
enlarged early endosomes. Importantly, these disease-associated
phenotypes were not detected in ﬁbroblast cultures from this case,
demonstrating the importance of studying these phenotypes in
iPSC-derived neurons. Taken together, these studies represent crit-
ical ﬁrst steps in assessing the potential of AD iPSCs to model
AD. As Israel et al. (2012) point out, generation of many addi-
tional sporadic AD iPSC lines will of course be needed to fully
establish the ability of this approach to guide drug development
and enhance our understanding of AD. The generation of directly
reprogrammed induced neural stem cells from AD patients may
also help to accelerate such research.
Another way to study neurological diseases, such as AD, is
the creation of the cybrid model. Mitochondrial DNA (mtDNA)
isolation from donors with subsequent transfer to immortal-
ized cells depleted of endogenous mtDNA creates cytoplasmic
hybrid (cybrid) cell lines that recapitulate at cellular and sub-
cellular levels any speciﬁc functional abnormalities characteristic
of the transferred mtDNA. The cybrid technique is useful both
in demonstrating the functional consequences of known mtDNA
mutations (Chomyn et al., 1994) and for screening for mtDNA
mutations in candidate diseases (Swerdlow and Hanna, 1996;
Swerdlow et al., 1996). Cybrid models, in which mtDNA from
platelets of living AD patients is expressed in replicating human
neural cells initially devoid of their own endogenous mtDNA
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FIGURE 5 | Non-transgenic animal model for AD.This model mimics early
stages of sporadic disease, which represents the vast majority of cases. The
model was obtained by interfering with the complex ADAM10/SAP97 for
2 weeks by means of a cell-permeable peptide strategy. This is sufﬁcient to
shift the metabolism of APP toward amyloidogenesis and allows the
reproduction of initial phases of sporadic AD.
(rho(0) cells) revealed that decreased cytochrome oxidase activ-
ity, increased oxidative stress, increased Aβ production, activation
of detrimental intracellular signaling and caspases, accelerated
mtDNA proliferation, and abnormal mitochondrial morphology
and transport can be transmitted through expression of mtDNA
from living AD patients (Onyango et al., 2006).
Many studies have applied to cells synthetic Aβ peptides to
create in vitro models. Many recent studies have used oligomers
of human Aβ prepared from synthetic Aβ peptides (Wang et al.,
2004), isolated from transfected cell lines (Walsh and Selkoe, 2007)
or puriﬁed frombrains affected byAD (Shankar et al., 2008). How-
ever, this AD in vitro models show some limitations, because the
research groups reported different results. This divergence could
depend on the form of Aβ because different Aβ assemblies or
conformation could have diverse targets.
COMPUTATIONAL MODELS
Another way to study a complex disease like AD is to model
the pathology with the assistance of bioinformatic. In physics
a complex system is a system in which the individual parts are
affected by local interactions, short range of action, which cause
changes in the overall structure. Science can detect local changes,
but cannot predict a future state of the system considered as a
whole. The complexity of brain dynamics may be too high for us
to conceptually understand the brain’s function in detail (Duch,
2007); computational model may collect a number of essential
features of brain dynamics leading to a model that behaves like
whole brain interactions and processes. Initially cognitive func-
tions were considered as a sequence of processing stage; perceptual
processes are followed by attentional processes that transfer infor-
mation to short-term memory and thus to long-term memory
(Atkinson and Shiffrin, 1968), and these are often represented as a
series of box-and-arrow diagrams. From this point of view, brain
dysfunctions are treated as disturbance in the information ﬂow.
In 1986 was published a “PDP book” (Parallel Distributed Pro-
cessing: Exploration in the Microstructure of Cognition), now
known as “connectionism,” in which authors focus the atten-
tion on the general proprieties of parallel information processing,
referring to the fact that a lot of different information can be
processed simultaneously, drawing analogies with human infor-
mation processing (McClelland and Rumelhart, 1986; McClelland
et al., 1995). The computational model based on this concept is
named neural network; this model is composed of array of simple
information-carrying units called nodes that respond to a par-
ticular set of inputs and produce a restricted set of outputs. The
responsiveness of a node depends on how strongly it is connected
to other nodes in the network and how active the other nodes
are. A network of nodes interacting with each other through con-
nections of different strengths, and each network node, called
an artiﬁcial neuron, may represent a single neuron of a speciﬁc
type, a generic neuron, a group of few neurons, a neural assem-
bly, or an elementary function realized in an unspeciﬁed way by
some brain area (Duch, 2007). Since AD is characterized by loss of
memory, neural model may represent a powerful tool to unravel
the relation between changes at cellular level and various clinical
manifestations of the disease (McClelland et al., 1995; Hasselmo
and McClelland, 1999).
The synaptic deletion and compensation model
The synaptic deletion and compensation model was conceived
initially by Horn and subsequently developed by Ruppin (Horn
et al., 1993; Ruppin and Reggia, 1995). The models of artiﬁcial
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neural progression of AD depart from the concept that cell death
in AD is generally limited within 10% of the neuronal population,
value that does not reﬂect the level of cognitive impairment of the
patients: the primary factor responsible for cognitive deﬁcits inAD
is the loss of approximately 50% of synaptic connections rather
than the mortality of neurons. Brain tries to compensate the loss
of these connections by strengthening the remaining; this mech-
anism is successful in the early stages of development of AD by
limiting the cognitive deﬁcits but not more in the terminal phase:
understanding how these two processes can inﬂuence memory,
and what the best compensation strategies that may slow down
the deterioration process are, represents the main questions of
this model. This model has demonstrated that the loss of synap-
tic connections gives rise to memory loss and distortion of the
learned pattern, even if the rate of memory deterioration can be
reduced by increasing the weight of the remaining connections for
a constant multiplication factor (Horn et al., 1996). Depending on
the compensation strategy after the same evolution period vari-
ous degrees of deterioration are obtained; this may explain why
patients with similar density of synaptic connections per unit of
cortical volume show quite different cognitive impairments.
The synaptic runaway model
This model was developed by Hasselmo (1991, 1997) and is
focused on a different phenomenon: in models of associative
memory, storing a memory as a pattern of neuronal spatiotem-
poral activation is associated with the storage of other connected
memories. The storage of a new memory activates analogs pat-
tern that can interfere with earlier associations if there was an
overlap between patterns or if the memory capacity is exhausted.
This interference results in a signiﬁcant increase in the number of
associations stored by the network that can also lead to a patholog-
ical increase of the strength of synaptic connections, which gives
rise to an increase of neuronal activity, high metabolic demand,
and eventually cells death, phenomenon known as excitotoxicity.
The model has also been used to show that in the brain there are
two separate mechanisms of memory, one for encoding and the
other for the recall, in order tominimize the excitotoxicity induced
interference. According to this hypothesis, the inhibitory and exci-
tatory cholinergic neuromodulation is the main factor controlling
the switching from one to another mode. Under normal con-
ditions the neuromodulation is sufﬁcient to prevent changes in
runaway synaptic modiﬁcation (RSM), while in pathological con-
ditions such AD the RSM is inevitable. Even healthy subjects may
run into RSMdue to overloading of memory. However, it has been
shown that the threshold levels for the initiation of RSM inAD are
much lower compared to controls (Siegle and Hasselmo, 2002).
CONCLUSION
Overall, these models have played a major role in deﬁning
critical disease-related mechanisms and in exploring novel poten-
tial therapeutic approaches. The purpose of neuroscientist is to
obtain helpful experimental model of human brain disorders
(Torres-Aleman, 2008), able to give the opportunity to reach
signiﬁcant advancements in the understanding of pathological
pathways, to characterize and study the molecular and biochem-
ical mechanisms that are impossible to study in human samples.
Current AD models rely on information gathered from inherited
forms of the disease, far less common than sporadic ones but
indistinguishable from the clinical point of view. Thus, both early
FAD and LOAD forms progressively develop cognitive deteriora-
tion that in early stages affect memory systems and at late phases
impair all cognitive spheres of daily life activities (Albert et al.,
1996).
We have described as invertebrate model systems have many
practical advantages for modeling human disease: short genera-
tion time, high fertility, readily available techniques for genetic
manipulation, ease of feeding therapeutics, and low cost of main-
tenance. These advantages make them amenable for large-scale
phenotype-based genetic screens and pharmacological manipula-
tions. Thus, they have been proven excellent systems for studying
the normal function of human genes and pathways linked to neu-
rodegenerative diseases such as AD and other tauopathies. In the
future, forward genetic screens using these models can help us
in better understanding the putative genes and pathways associ-
ated with AD. When pairing the information we can gather from
these “simple” invertebrate models systems with their vertebrate
counterparts such as mice and rats, an enhanced determina-
tion of which speciﬁc experimental approaches to be taken, or
future directions for the ﬁeld can be achieved. Ultimately, this
will be translated into the discovery of novel gene targets and
novel diagnostic and therapeutic strategies against AD and other
dementias.
As vertebrate model we highlight the main advances that
zebraﬁsh offers in order to understand the pathological mecha-
nisms of AD. This vertebrate is an interesting tool that can be
strategically incorporated into the analysis of the neurodegenera-
tion cascade, covering the existing gap between the drug discovery
in cellularmodels and the preclinical assays in rodents. In any case,
zebraﬁsh should be used in large scale before pharmacological
validation in rodent models, especially because of its larva–adult
duality. Although we have provided diverse examples to demon-
strate the scope for zebraﬁsh to model AD, several pieces of the
puzzle are still lacking. For example, a better understanding of the
comparative brain anatomy and physiology of adult zebraﬁsh will
be required, and more transgenic zebraﬁsh to model an AD-like
pathology are a current need. So a more effort must be done to
deﬁnitely optimize the zebraﬁsh as a valid model for AD.
As in human, transgenic mice show an overexpression of Aβ
and development of senile plaques; the main observation aris-
ing from mouse model was that an excess of Aβ is enough to
induce cognitive impairment and synaptic dysfunction even in the
absence of NTFs or neuronal loss (Gotz et al., 2004), conﬁrming
that Aβ overproduction must trigger AD, before tau deposition.
This ﬁnding substantiated the amyloid cascade hypothesis of AD.
According to this hypothesis, accumulation of Aβ in the brain is
the primary inﬂuence driving the disease pathogenesis (Hardy and
Selkoe, 2002). The rest of the disease process, including formation
of neuroﬁbrillary tangles, is proposed to result from an imbalance
between Aβ production and Aβ clearance. Some of the strongest
data supporting tau pathology as a downstream event of Aβ accu-
mulation have come from studies in 3xTg mice. In these mice,
the appearance of intraneuronal Aβ precedes somatodendritic
accumulation of tau (Oddo et al., 2004). Furthermore, removal
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of intraneuronal Aβ via immunotherapy leads to the removal of
somatodendritic tau shortly afterward (Oddo et al., 2004). Trans-
genic mice have also allowed us to study aspects of the disease
that are inaccessible in humans, as the correlation between synap-
tic deﬁcits and disease’s progression. In accordance with amyloid
hypothesis of AD (Hardy and Selkoe, 2002) the species responsible
for synaptic and cognitive dysfunction are soluble Aβ oligomers,
and this can explain the lack of correlation between the number of
Aβ plaques and the degree of dementia in humans and the heavy
correlation with low-molecular-weight soluble Aβ species (Funato
et al., 1999; McLean et al., 1999; Klein et al., 2001). Several groups
conducted deep cognitive investigation in transgenic mice and the
results are in line with this ﬁnding: mice at different age do not
display any correlation between the number of senile plaques and
memory dysfunction, moreover cognitive deﬁcits precede plaque
deposition (Westerman et al., 2002; Van Dam and De Deyn, 2006;
Balducci et al., 2010).
Due to the complexity of the disease, no transgenic line is able
to recapitulate all aspects of the pathology, suggesting probably
the limitation of using a rodent system to reproduce a human
disease process that take several decades to develop and which
primarily involves higher cognitive function. Many factors may
affect the ability of transgenicmice tomodel human disease. These
include obvious anatomical and morphological differences as well
as the possibly difference in critical protein such as tau or APP
(Gama Sosa et al., 2012). The main question arising from this
evidence is whether transgenic mice do really mirror the tem-
poral proﬁle of the neuropathological process of human AD. All
age-related neurodegenerative disease develop in context of aging,
that is believed to be the results of the gradual loss metabolic and
genetic assets necessary to preserve the integrity and functionality
of all cellular components (Ljubuncic and Reznick, 2009); fur-
thermore non-physiological 5–10-fold overexpression of human
APP in transgenic mice could accelerate the pathological role of
the overexpressed protein, while in human an increase of 50% is
enough for amyloid plaques deposition (Duff and Suleman, 2004).
Another important difference betweenmice andADpatients is the
structure of the Aβ deposition; mice show a compact core plaques
while in human the core density is lower and the morphology
amorphous (Roher and Kokjohn, 2002). Regarding soluble Aβ
oligomers, biochemical analysis indicated that there are difference
not only between humans and mice, but also among transgenic
lines; in this frame, it is interesting to point out again that differ-
ent genetic strains may produce different amounts of Aβ, forming
potentially different oligomeric forms and in different genetic
background.
In light of these considerations, we should take into consider-
ation non-transgenic AD mice models, For instance, interfering
with synaptic ADAM10 localization/activity for 2 weeks affects
APP metabolism, increasing APP amyloidogenic cleavage with a
modest but signiﬁcant raise of Aβ release and of low-n Aβ aggre-
gate production (Epis et al., 2010). This subtle increase in Aβ
appears particularly promisingwhen comparedwithdata collected
from studies in engineered animal models, where accumulation of
solubleAβ is normally reported in older animals, i.e., 9–13months
of age (Holcomb et al., 1998; Oddo et al., 2003a). Similarly, even
in triple transgenic mice, Aβ oligomers can be revealed after
13 months of age (Oddo et al., 2003b, 2006). Notably, in this non-
transgenic model, the slight increase of both soluble Aβ and its
low-n aggregates is evident after just 2 weeks of treatment, thus it
appears as a promising model to study early phases of AD.
New perspectives are also emerging to deal with the difﬁculties
of modeling AD pathology.
A growing amount of evidence suggests that stem cell-based
therapies could prove beneﬁcial in AD, albeit via indirect mech-
anisms rather than cellular replacement. Studies of embryonic,
neural, and iPSCs are also beginning to unravel the normal and
pathogenic function of AD-associated genes and may provide
powerful new approaches to model this disorder. Future work
will hopefully clarify the potential of stem cells to treat AD and
decipher the complex genetic differences that predispose a person
to developing this devastating disease.
We have also described two computational models that can
be seen as complementary rather than competitive. The AD may
develop through different routes: on the one hand the loss of
synapses and an insufﬁcient compensation lead to small brain
damage, the other the synaptic runaway may lead to death of
hyperactive neurons with signiﬁcant structural damage of the
brain. The assumption that computational model reﬂects real
neural mechanism leads to several therapeutics suggestions: they
may help to slow down the degeneration of synaptic connections
and thus the development of the disease in its early stage (Duch,
2000, 2007). Furthermore, neural model provide a new level of
reasoning about brain disease level that cannot be adequately
described in the language of psychiatry or psychopharmacology
(Duch, 1997).
In conclusion the development of adequate animal models
mimicking all stages of AD progression and merging convergent
pathways of pathogenesis still represents a need for research on
AD. However, the complementary use of several models, with dis-
tinct pros and contras, will help to understand the molecular basis
of the AD, and to develop novel strategies for AD prevention and
therapy.
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